David Kirn
MD
Co-Founder and CSO
👥Biography 个人简介
David Kirn co-developed pexastimogene devacirepvec (JX-594, Pexa-Vec) — a GM-CSF-expressing oncolytic vaccinia virus — including clinical development demonstrating objective responses and survival benefit signals in advanced hepatocellular carcinoma. His foundational work on optimizing oncolytic viruses for therapeutic activity and his clinical development programs contributed to advancing vaccinia-based oncolytic therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 David Kirn 的研究动态
Follow David Kirn's research updates
留下邮箱，当我们发布与 David Kirn（Jennerex / SillaJen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment